Charles Schwab Investment Management Inc. Has $4.50 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Charles Schwab Investment Management Inc. grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 321,263 shares of the company’s stock after acquiring an additional 6,171 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of SI-BONE worth $4,504,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Bellevue Group AG boosted its stake in SI-BONE by 4.1% in the 3rd quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock valued at $20,189,000 after purchasing an additional 56,500 shares during the period. State Street Corp grew its stake in shares of SI-BONE by 5.1% in the third quarter. State Street Corp now owns 1,081,871 shares of the company’s stock valued at $15,125,000 after acquiring an additional 52,972 shares in the last quarter. Wellington Management Group LLP increased its position in SI-BONE by 3.5% during the third quarter. Wellington Management Group LLP now owns 1,028,238 shares of the company’s stock worth $14,375,000 after acquiring an additional 35,220 shares during the period. Geode Capital Management LLC raised its stake in SI-BONE by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock worth $12,921,000 after purchasing an additional 30,005 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock valued at $11,791,000 after purchasing an additional 220,555 shares during the period. Institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SIBN shares. Truist Financial reaffirmed a “buy” rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Needham & Company LLC upped their target price on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE presently has an average rating of “Buy” and a consensus target price of $24.50.

Insider Activity

In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the transaction, the insider now owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,311 shares of company stock worth $130,356. Corporate insiders own 3.90% of the company’s stock.

SI-BONE Stock Down 0.9 %

Shares of SIBN opened at $14.68 on Wednesday. The firm has a 50 day simple moving average of $16.57 and a two-hundred day simple moving average of $14.79. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16. The company has a market cap of $623.21 million, a P/E ratio of -15.96 and a beta of 1.17.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. Research analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.